Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.

Notably, eight genes were consistently identified across both platforms (BAIAP2L2, EEF1A2, EPHA7, HNF1B, MMP24, PTHLH, SAA2, and VNN1) and were highly significant (hypergeometric test, p-value = 1.97 × 10− 12 , 89-fold enrichment over expected by chance), validating the consistency of our findings across different technological platforms (supplementary Table 2).

also in 132,142 other papers

n = 8; p = 0.142), although this difference did not reach statistical significance (supplementary Fig. 7b).

also in 111,027 other papers